Hepatic enzyme abnormalities in children on triple therapy for tuberculosis

Pediatric Pulmonology

Volumn 27, Issue 1, 1999, Pages 37-42

  Corrigan, Donna ^a,b   Paton, James ^a  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b QUEEN MOTHER S HOSPITAL   (United Kingdom)

Author keywords

Children; Hepatotoxicity; Treatment; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILD; CLINICAL ARTICLE; HUMAN; INFANT; LIVER FUNCTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TUBERCULOSIS;

ADOLESCENT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; ISONIAZID; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MONITORING, PHYSIOLOGIC; PROGNOSIS; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS;

EID: 0032947758     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0496(199901)27:1<37::AID-PPUL8>3.0.CO;2-G     Document Type: Article

References (32)

1. Ormerod LP, Citron KM, Darbyshire JH, Smith ML. Chemotherapy and management of tuberculosis in the United Kingdom: Recommendations of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax 1990;45:403-408.
2. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-1374.
3. British National Formulary. March ed. 1997: 5.1.9. pp 254-258.
4. Committee on Safety of Medicines. Fatal hepatic reactions with drug therapy for tuberculosis. CSM 1993;19.
5. Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1978;59: 13-32.
6. Ormerod LP, Skinner C, Wales J. Hepatotoxicity of antituberculosis drugs. Thorax 1996;51:111-113.
7. Stein MT, Liang D. Clinical hepatotoxicity of isoniazid in children. Pediatrics 1979;64:499-505.
8. Litt IF, Cohen MI, McNamara H. Isoniazid hepatitis in adolescents. J Pediatr 1976;89:133-135.
9. Byrd RB, Horn BR, Solomon DA, Griggs GA. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. JAMA 1979;241: 1239-1241.
10. Rapp RS, Campbell RW, Howell JC, Kendig EL. Isoniazid hepatotoxicity in children. Am Rev Respir Dis 1978;118:794-796.
11. Pallusci VJ, O'Hare D, Lawrence RM. Hepatotoxicity and transaminase measurement during isoniazid chemoprophylaxis in children. Pediatr Infect Dis J 1995;14:144-148.
12. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampicin - A meta-analysis. Chest 1991;99:465-471.
13. Rugmini PS, Mehta S. Hepatoloxicity of isoniazid and rifampicin in children. Indian Pediatr 1984;21:119-126.
14. Martinez-Roig A, Cami J, Llorens-Terol J, de la Torre R, Perich F. Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children. Pediatrics 1986;77:912-915.
15. Linna O, Uhari M. Hepatotoxicity of rifampicin and isoniazid in children treated for tuberculosis. Eur J Pediatr 1980;134:227-229.
16. Kumar A, Misra PK, Mehotra R, Govil YC, Rana GS. Hepatotoxicity of rifampicin and isoniazid: Is it all drug-induced hepatitis? Am Rev Respir Dis 1991;143:1350-1352.
17. O'Brien RJ, Long MW, Cross MA, Snider DE. Hepatotoxicity from isoniazid and rifampicin among children treated for tuberculosis. Pediatrics 1983;72:491-499.
18. American Academy of Pediatrics - Committee on Infectious Diseases. Chemotherapy for tuberculosis in infants and children. Pediatrics 1992;89:161-165.
19. Turktas H, Unsal M, Tulek N, Ortuc O. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis. Tuberc Lung Dis 1994;75:58-60.
20. Ormerod LP, Horsefield N. Frequency and type of reactions to antituberculosis drugs: Observations in routine treatment. Tuberc Lung Dis 1996;1:37-42.
21. Gronhagen-Riska C, Hellstrom P-E, Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampicin treatment of tuberculosis. Am Rev Respir Dis 1978;118:461-466.
22. Patel AM, McKeon J. Avoidance and management of adverse reactions to antituberculosis drugs. Drug Safety 1995;12:1-25.
23. Dossing M, Wilcke JTR, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: An 11-year study. Tuberc Lung Dis 1996;77:335-340.
24. Thompson NP, Caplin ME, Hamilton MI, Gillespie SH. Clarke SW, Burroughs AK, McIntyre N. Anti-tuberculosis medication and the liver: Dangers and recommendations in management. Eur Respir J 1995;8:1384-1388.
25. Centers for Disease Control. Adverse drug reactions among children treated for tuberculosis. MMWR 1980;29:589-591.
26. Mitchell JR, Zimmerman HJ, Ishak KG. Thorgeirsson UP, Snodgrass WR, Nelson SD. Isoniazid liver injury: Clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976;84:181-192.
27. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975;69:289-302.
28. O'Brien RJ. Hepatotoxic reactions to antituberculosis drugs: Adjustments to therapeutic regimens. JAMA 1991;265:3323.
29. Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: A case-control study. Thorax 1996;51:132-136.
30. Singh J, Arora A, Garg PK, Thakur VS, Pande JN, Tandon RK. Antituberculosis treatment-induced hepatotoxicity: Role of predictive factors. Postgrad Med 1995;71:359-362.
31. Ali J. Hepatotoxic effects of tuberculosis therapy. Postgrad Med 1996;99:217-236.
32. Whittington RM. Fatal hepatotoxicity of anti-tubercular chemotherapy. Lancet 1991;338:1083-1084.